1. 2006 Revenue continued to depend on a relatively small number of products
APRIL 2007
SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS Your use of these materials is subject to the terms and conditions hereof. Please read the disclaimer carefully before using these materials.

2. to sales derived from products first marketed in the previous 5 years
Chapter 1
Overview
Figure 1.5
2006 Revenue continued to depend on a relatively small number of products
Median percentage of sales in 2006 attributable to the Top 3 products and
to sales derived from products first marketed in the previous 5 years
Key message
Mid and Other companies appear to derive approximately 11% more of their sales from their Top 3 products than Major companies confirming the generally greater breadth of major company portfolios. Only 16% of pharma sales come from medicines launched in the last five years, suggesting significant potential exposure to patent expiry. Supporting this conclusion, a recent independent report noted that a comparably high proportion of major pharma revenues come from medicines that have been on the market for more than five years1
Methodology
Presented is the percentage of sales in 2006 attributable to the Top 3 products calculated as a median from data supplied by 22 companies (10 Major and 12 Mid and Other). Also presented is the percentage of sales in 2006 from products marketed in the last five years calculated as a median from the data supplied by 21 companies (9 Major and 12 Mid and Other).
Key Definitions
Global pharmaceutical sales: The revenue from global sales of ethical pharmaceuticals. This includes finished products, bulk sales and royalties from licensed-out ethical pharmaceuticals
CMR International Performance Metrics Programme / Source
Industry R&D Investment Programme
1 Pharma 2020: The Vision, Which Path Will You Take? PriceWaterhouseCoopers 2007
n is the number of companies that are represented in the data
Major companies are defined as those spending ≥US$ 1.8 billion in 2006 on ethical pharmaceutical R&D.
Mid and Other companies are defined as those spending <US$ 1.8 billion in 2006 on ethical pharmaceutical R&D.
SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS

3. Terms of Use and Disclaimer
The materials contained in these slides may be used for your own use in presenting at conferences and meetings or for inclusion in reports provided that you acknowledge the source of the materials and include the following statement: “2008 © Thomson Reuters. Some of the materials and/or data in this [report, presentation, paper etc] are reproduced under a license from Thomson Reuters. You may not copy or re-distribute these materials in whole or in part without the written consent of Thomson Reuters”.
Charts, graphs, and illustrations contained in these slides may not be decompiled, reverse engineered, or disassembled.
The copyright and other intellectual property rights in these slides is owned by Thomson Reuters or its licensors. Except for the license set out in these Terms of Use, Thomson Reuters neither assigns any rights nor grants any licenses or rights in respect of these slides to you and any use of these slides other than in accordance with these Terms of Use is subject to Thomson Reuters’ prior written consent. For additional permissions, please contact: [contact ]
THOMSON REUTERS MAKES NO WARRANTY OR REPRESENTATION AS TO THE ACCURACY, COMPLETENESS OR CORRECTNESS OF ANY MATERIALS CONTAINED WITHIN THESE SLIDES OR THAT ALL ERRORS IN THE SLIDES OR THE MATERIALS CONTAINED WITHIN THESE SLIDES WILL BE CORRECTED.
THOMSON REUTERS IS AN INFORMATION PROVIDER AND DOES NOT PROVIDE LEGAL, FINANCIAL OR OTHER PROFESSIONAL ADVICE. THE MATERIALS CONTAINED IN THESE SLIDES ARE FOR GENERAL INFORMATION PURPOSES ONLY, ARE NOT INTENDED TO CONSTITUTE LEGAL OR OTHER PROFESSIONAL ADVICE, AND SHOULD NOT BE RELIED ON OR TREATED AS A SUBSTITUTE FOR SPECIFIC ADVICE RELEVANT TO PARTICULAR CIRCUMSTANCES. THOMSON REUTERS SHALL NOT BE LIABLE FOR ANY LOSS THAT MAY ARISE FROM ANY RELIANCE BY YOU, YOUR EMPLOYER OR CLIENT, OR ANY OTHER THIRD PARTY, ON THE MATERIALS CONTAINED IN THESE SLIDES.
THOMSON REUTERS WILL NOT BE LIABLE IN CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE FOR ANY INDIRECT, SPECIAL, PUNITIVE OR CONSEQUENTIAL LOSS OR DAMAGE ARISING OUT OF OR IN CONNECTION WITH THESE TERMS OF USE OR YOUR USE OF THE SLIDES, HOWEVER SUCH INDIRECT LOSS OR DAMAGE MAY ARISE.
You shall not assign, sub-licence or delegate any of your rights or obligations under these Terms of Use without the prior written consent of Thomson Reuters; any assignment, sub-licensing or delegation in breach of these Terms of Use shall be null and void. If any provision of these Terms of Use are determined to be illegal or unenforceable by any court of competent jurisdiction it shall be deemed to have been deleted without affecting the remaining provisions. These Terms of Use will be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania. You hereby irrevocably submit to the exclusive jurisdiction of the federal and state courts located in Philadelphia, PA, USA.